NDA (New Drug Application)
ANDA (Generic Application)
Track protection status across key markets to assess launch feasibility.
It is formulated by 1 pharmaceutical company such as CHEMOCENTRYX. It is marketed under 1 brand name, including TAVNEOS. Available in 1 different strength, such as 10MG, and administered through 1 route including CAPSULE;ORAL. The latest reported annual revenue is $23,453,841 in 2024.
API availability: Loading API feasibility...
Licensing: 1 potential partnersUS Launch window: Loading launch window...
Stay ahead with worldwide patent expiry and latest updates.
FDA approval history for this ingredient
Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.
Key expiration dates for US patents covering this ingredient
Stay ahead with worldwide patent expiry insights, market data, and research updates.
Latest drug strengths approved by FDA
| Strength | Route of Administration | Companies | Latest Approval Date |
|---|
Patents approved by the FDA for the ingredient
|
|
Patent Number | Publication Date | Legal Status | Patent Expiry Date | |
|---|---|---|---|---|---|
| {"application_id":"51309","ingredient":"AVACOPAN","trade_name":"TAVNEOS","family_id":"179d2b839e574722a2b5","publication_number":"US8906938B2","cleaned_patent_number":"8906938","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-12-21","publication_date":"2014-12-09","legal_status":"Granted"} | US8906938B2 Molecular Formulation | 09 Dec, 2014 | Granted | 21 Dec, 2029 | |
| {"application_id":"51363","ingredient":"AVACOPAN","trade_name":"TAVNEOS","family_id":"179d2b839e574722a2b5","publication_number":"US8445515B2","cleaned_patent_number":"8445515","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-02-03","publication_date":"2013-05-21","legal_status":"Granted"} | US8445515B2 Molecular Formulation | 21 May, 2013 | Granted | 03 Feb, 2031 | |
| {"application_id":"123298","ingredient":"AVACOPAN","trade_name":"TAVNEOS","family_id":"","publication_number":"US11951214B2","cleaned_patent_number":"11951214","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2039-11-27","publication_date":"2024-04-09","legal_status":"Granted"} | US11951214B2 Formulation | 09 Apr, 2024 | Granted | 27 Nov, 2039 | |
| {"application_id":"112580","ingredient":"AVACOPAN","trade_name":"TAVNEOS","family_id":"dccff76b3d244a08b28e","publication_number":"US11603356B2","cleaned_patent_number":"11603356","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2041-05-29","publication_date":"2023-03-14","legal_status":"Granted"} | US11603356B2 Molecular Formulation | 14 Mar, 2023 | Granted | 29 May, 2041 |
Country wise drug prices over the years
Country wise drug revenue over the years
Latest clinical trials and research studies for this ingredient
| NCT ID | Title | Status | Phase | Conditions | Start Date | Completion Date |
|---|
Manufacturing Locations
Unlock access to all suppliers of Avacopan
Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.